Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 40 | Mind Blowing Facts

Baidu (NASDAQ:BIDU) reported a return to revenue growth in its first quarter of 2026, with management emphasizing that artificial intelligence has become the company’s primary growth engine and now accounts for a majority of its general business revenue. Co-founder and Chief Executive Robin Li said

MarketBeat

Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1

Berkshire Hathaway has a new top dog. Its appears that Greg Abel is barking loudly, upending much of the company's huge investment portfolio.

MarketBeat

Insider Buying Says Upstart Isn’t Down for the Count

Upstart is a growing fintech with the potential to accelerate growth and begin taking share from its larger competitors, driven by an AI-powered platform.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Niu Technologies Q1 Earnings Call Highlights

Niu Technologies (NASDAQ:NIU) reported a sharp increase in first-quarter 2026 revenue and China sales volume, as management said growth in electric motorcycles offset weakness in electric bicycles during a period of regulatory transition. Chief Executive Officer Yan Li said total sales volume reach

MarketBeat

iQIYI Q1 Earnings Call Highlights

iQIYI (NASDAQ:IQ) reported first-quarter 2026 revenue of CNY 6.2 billion, down 8% sequentially, as the Chinese streaming company emphasized artificial intelligence, overseas growth and new content formats as central parts of its strategy. Founder, Director and CEO Gong Yu said the company is operat

MarketBeat

NRx Pharmaceuticals Q1 Earnings Call Highlights

NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder,

MarketBeat

Gossamer Bio Q1 Earnings Call Highlights

Gossamer Bio (NASDAQ:GOSS) said it is moving ahead with plans to seek U.S. approval for seralutinib in pulmonary arterial hypertension, outlining a September 2026 target for a New Drug Application submission while also detailing new imaging data and steps to address its balance sheet during its firs

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

These Stocks Could Be the Biggest Winners of the 2026 Midterms

Defense, healthcare, and financial stocks may outperform ahead of midterm elections as investors position for policy shifts

MarketBeat

3 Infrastructure Stocks Fueling the Data Center Building Boom

Infrastructure companies are benefiting from the data center boom, reporting strong Q1 2026 earnings and raising full-year guidance. Here are 3 to watch.

MarketBeat

J.B. Hunt Says Freight Rates Are Rising as Capacity Tightens, Not Demand

Executives from J.B. Hunt Transport Services (NASDAQ:JBHT) said freight-market conditions are tightening, but they attributed much of the shift to capacity leaving the market rather than a broad-based demand rebound. Speaking at a Bank of America transportation conference, Brad Hicks, executive vic

MarketBeat

Kainos Group H2 Earnings Call Highlights

Kainos Group (LON:KNOS) said it has returned to growth after reporting stronger sales, revenue and backlog for the year ended March 31, 2026, with management highlighting broad-based momentum across its three divisions. Brendan, who led the presentation alongside Richard, said the main message from

MarketBeat

Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks

Datadog and Dynatrace are two key names in the AI observability arena. One is hitting all-time highs, while the other remains down in the dumps.

MarketBeat

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

MarketBeat

iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains

iRhythm Technologies (NASDAQ:IRTC) executives said the company is seeing continued business momentum after a favorable Medicare coverage update, a stronger-than-expected first quarter and progress on several product and margin initiatives. Speaking at an investor event, Stephanie Zhadkevich, senior

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals (NASDAQ:IONS) products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocri

MarketBeat

SMA Solar Technology Q1 Earnings Call Highlights

SMA Solar Technology (ETR:S92) reported a modest increase in first-quarter 2026 sales and operating profitability, while narrowing its full-year outlook toward the upper end of its prior guidance range as demand in its large-scale business remained strong and momentum improved in its Home and Busine

MarketBeat

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended

MarketBeat

Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, late-stage pipeline activity and potential launches across oncology and immunology. Speaking at the

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare Conf

MarketBeat

InterDigital Maps Path to $1B Recurring Revenue on Patents, Streaming Push

InterDigital (NASDAQ:IDCC) Chief Financial Officer Rich Brezski outlined the company’s patent licensing model, recent financial performance and long-term growth targets during a presentation at the 21st Annual Needham Technology, Media, and Consumer Conference. Brezski described InterDigital as “fi

MarketBeat

Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears

Integra LifeSciences (NASDAQ:IART) is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief executive officer, Chief Financial Officer Lea Knight said during a Bank of America med tech conference discussion hosted by analyst Rei Tan.

MarketBeat

Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness

Henry Schein (NASDAQ:HSIC) executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season. Speaking at a Bank of America h

MarketBeat

Horizon Quantum Computing Pte. Lays Out Quantum Software Push at Needham Conference

Horizon Quantum Computing Pte. (NASDAQ:HQ) used its appearance at Needham & Company’s 21st annual Technology, Media, & Consumer Conference to outline its strategy as a newly public quantum software company focused on building infrastructure for developers, hardware providers and end users. Needham

MarketBeat

GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead

GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company’s CFO, at a Bank of America event. Aaron said t

MarketBeat

Green Plains Touts Operational Gains, Carbon Capture Upside at Conference

Green Plains (NASDAQ:GPRE) executives said the company’s recent performance has been driven by tighter operating discipline, a simplified business structure and new opportunities tied to carbon capture and federal biofuels incentives. Speaking at a company event, Chief Financial Officer Ann Reis sa

1 … 39 40 41 42

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Cancer

23,870 stories

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.